Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC40A1 | Q9NP59 | 11/20 | 0.79 |
| ▸ | CKS1B | P61024 | 7/20 | 0.70 |
| ▸ | SKP2 | Q13309 | 7/20 | 0.70 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.64 |
| ▸ | MEN1 | O00255 | 2/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.61 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11972688 | 0.88 | SLC40A1 (1.00) | SLC40A1CKS1BSKP2GLO1MEN1 | |
| SCHEMBL11995650 | 0.85 | SLC40A1 (1.00) | SLC40A1CKS1BSKP2GLO1MEN1 | |
| SCHEMBL17506517 | 0.82 | CKS1B (1.00) | SLC40A1CKS1BSKP2GLO1 | |
| SCHEMBL17506530 | 0.81 | CKS1B (1.00) | SLC40A1CKS1BSKP2GLO1 | |
| SCHEMBL17506543 | 0.81 | CKS1B (1.00) | SLC40A1CKS1BSKP2GLO1 | |
| SCHEMBL17570174 | 0.79 | SLC40A1 (0.70) | SLC40A1CKS1BSKP2GLO1MEN1 | |
| SCHEMBL27214254 | 0.79 | SLC40A1 (0.74) | SLC40A1GLO1MEN1KMT2ATDP1 | |
| SCHEMBL30925462 | 0.79 | SLC40A1 (1.00) | SLC40A1CKS1BSKP2GLO1MEN1 | |
| SCHEMBL11973652 | 0.79 | SLC40A1 (1.00) | SLC40A1CKS1BSKP2GLO1MEN1 | |
| SCHEMBL30925439 | 0.79 | SLC40A1 (0.70) | SLC40A1CKS1BSKP2GLO1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120214803-A1 | Novel Sulfonaminoquinoline Hepcidin Antagonists | VIFOR (INTERNATIONAL) AG (CH) | 2012-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214803-A1 | Novel Sulfonaminoquinoline Hepcidin Antagonists | HAMP, SLC40A1, FTH1 | SLC40A1 2/4885CKS1B 3744/4885SKP2 346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.